Vitiligo is a chronic skin depigmentation disorder characterized by the destruction or loss of function of melanocytes. Its etiology and pathophysiology are not well understood but are believed to be driven by autoimmune processes. Because vitiligo affects patients’ appearance, the disease burden is high. Until 2022, no therapies were approved to treat it; topical corticosteroids or other immunomodulators alone or in combination with narrow-band UVB to induce repigmentation were the mainstay treatments for vitiligo patients. However, these treatments offer only modest clinical benefit and can have troublesome side effects. The FDA’s July 2022 approval of Incyte’s Opzelura (topical ruxolitinib) gives patients the first approved pharmacological treatment for repigmentation in vitiligo. The FDA approved Opzelura cream for the treatment of nonsegmental vitiligo in adult and pediatric patients 12 or older. Our Treatment Algorithms study provides national patient-level claims data to explore the use of key therapies in both newly diagnosed and recently treated patients, providing insight into the current treatment landscape for vitiligo.
Questions answered
Geography: United States
Key drugs covered: Opzelura, key topical corticosteroids, calcineurin inhibitors
Product description
Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.
Key feature
Dashboard featuring interactive visuals, easy navigation, and expanded analyses